%0 Journal Article
%A Pfaff, Elke
%A Kessler, Tobias
%A Balasubramanian, Gnana Prakash
%A Berberich, Anne
%A Schrimpf, Daniel
%A Wick, Antje
%A Debus, Jürgen
%A Unterberg, Andreas
%A Bendszus, Martin
%A Herold-Mende, Christel
%A Capper, David
%A Schenkel, Irini
%A Eisenmenger, Andreas
%A Dettmer, Susan
%A Brors, Benedikt
%A Platten, Michael
%A Pfister, Stefan
%A von Deimling, Andreas
%A Jones, David
%A Wick, Wolfgang
%A Sahm, Felix
%T Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.
%J Neuro-Oncology
%V 20
%N 6
%@ 1523-5866
%C Oxford
%I Oxford Univ. Press
%M DKFZ-2018-00653
%P 826 - 837
%D 2018
%Z Pfaff E*, Kessler T*  (*first author") / David T. W. Jones,# Wolfgang Wick,# and Felix Sahm# last authors
%X O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is a predictive biomarker in glioblastoma patients. Glioblastoma without hypermethylated MGMT promoter is largely resistant to treatment with temozolomide. These patients are in particular need of new treatment approaches, which are offered by biomarker-driven clinical trials with targeted drugs based on molecular characterization of individual tumors.In preparation for an upcoming clinical study, a comprehensive molecular profiling approach was undertaken on tissues from 43 glioblastoma patients harboring an unmethylated MGMT promoter at diagnosis. The diagnostic pipeline covered various levels of molecular characteristics, including whole-exome sequencing, low-coverage whole-genome sequencing, RNA sequencing, as well as microarray-based gene expression profiling and DNA methylation arrays.Complex multilayer molecular diagnostics were feasible in this setting with a median turnaround time of 4-5 weeks from surgery to the molecular tumor board. In 35
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:29165638
%2 pmc:PMC5961072
%R 10.1093/neuonc/nox216
%U https://inrepo02.dkfz.de/record/134863